Objectives: To investigate the prescription of potentially addictive drugs, including analgesics and CNS depressants, to women exposed to intimate partner violence (IPV).
Article focus
• Cross-sectional studies have suggested that intimate partner violence (IPV) is associated with increased medication use in women.
• Although substance abuse is common among women who have experienced IPV, former studies have not addressed the prescription of drugs with addiction potential.
• We assessed the relationship of IPV to prescription rates for potentially addictive drugs, including analgesics and CNS depressants, for women in Oslo, Norway.
Key messages
• This longitudinal study showed that women exposed to intimate partner violence, including psychological violence alone, more often received prescriptions for potentially addictive drugs compared to non-exposed women.
• Prescription rates were increased both for potentially addictive analgesics and CNS depressants.
• Women who had experienced IPV more often received prescriptions from multiple physicians.
Strengths and limitations of this study
• A major strength is the prospective and accurate measurement of drug prescriptions from a national register. The study is population based, and adds new information about the prescription of restricted drugs with verified addictive potential to women exposed to intimate partner violence.
• Limitations of the study include the low participation rate, and the lack of prescription data 
Introduction
Intimate partner violence (IPV) is associated with a broad range of physical and mental health problems in women, including injuries, chronic pain, depression, anxiety, sleep disorders, and substance abuse. [1] [2] [3] [4] Cross-sectional studies further indicate that women who have experienced violence from an intimate partner are more likely to use analgesic and psychotropic drugs. 2, 5, 6 These drugs can be of clinical benefit in treatment of pain, mental distress, and insomnia; however, they do also have several adverse effects. Some of them, such as opioid analgesics and benzodiazepines, may within few weeks of use lead to physical and psychological addiction. 7, 8 The development of drug tolerance will additionally result in decreasing effectiveness and increasing dose requirements over time. Due to potential dependence and abuse the authorities have implemented control measures to restrict prescriptions for potentially addictive drugs. 9 Still, the overall prescription has increased during the past decade. 9, 10 There is limited research linking IPV and use of prescription drugs. The current knowledge is primarily based on self-reported drug use from cross-sectional studies. 2, 5, 6, 11 Although substance abuse is common among women who have experienced IPV, 1,12 previous studies have not addressed prescription of drugs with addiction potential. Former research has also mostly been restricted to IPV comprising physical or sexual violence. 3, 13 However, recent findings indicate that psychological violence by an intimate partner is common and associated with adverse health outcomes irrespective of whether it is accompanied with physical or sexual violence. We did a longitudinal analysis of register-based prescription data from women in Oslo,
Norway. The aim was to assess the prescription rates for potentially addictive drugs, including analgesics and CNS depressants, to women exposed to physical and/or sexual IPV and psychological IPV alone.
Methods

Data sources
Our study sample was a population based cohort of women who participated in the Oslo Records from NorPD cover all prescriptions dispensed from Norwegian pharmacies to individuals treated in ambulatory care. 15 Drugs are classified according to the Anatomical Therapeutic Chemical (ATC) classification. 16 Data from NorPD include encrypted identifiers for patients and prescribers, ATC code, defined daily dose (DDD), date of dispensing, and if applicable reimbursement code. The indication for prescription is not recorded, but the reimbursement code may in some cases indicate the patient's diagnosis. The DDD determined by the WHO collaborating centre for drug statistics is the assumed average maintenance dose per day for a drug used for its main indication in adults. 16 Person-time at risk was calculated using information on respondents' month/year of death and emigration from Statistics Norway until 1. The Oslo Health Study was conducted under the joint collaboration of the Norwegian Institute of Public Health, the University of Oslo and the Municipality of Oslo. Details about the design, the questionnaires and data collection procedures are described previously, and information is available at the web page of the Norwegian Institute of Public Health. 5, 17, 18 A main questionnaire and an invitation to attend a health screening were mailed to all citizens from selected birth cohorts. Additional questionnaires were distributed at the screening stations to be answered by the participants at home and returned by mail in a pre-paid envelope. The HUBRO questionnaires covered sociodemographics, current and past health, lifestyle, health service utilization, medication use, and life events. The additional questionnaires also included questions about violence, and were addressed to women born in 1940, 1941, 1955, 1960 and 1970 . Totally, 16926 women in these age groups were invited to participate, of whom 8094 (48%) attended screening. Still, eligibility into our study required that women had answered at least one question about violence (figure 1 
Statistical analysis
Crude and multivariable-adjusted prescription rate ratios (RR) were estimated with Poisson models with number of prescriptions as outcome. Due to overdispersion we used the negative binomial models. Many women did not receive any medicine, that is a large part with zero count, and if the Vuong test favoured a zero-inflated negative binomial model we used this.
The women were at risk for medicine prescriptions from January 1, 2004 until death/emigration or December 31 2009. The logarithm of months of follow-up in Nor PD was used as offset to allow for differing follow-up duration. The models included a priori defined covariates: Model 1 adjusted for age, education, paid employment, and marital status, while model 2 additionally included former chronic musculoskeletal pain, mental distress, and sleep problems. Analyses were restricted to women with complete data on included variables.
Univariate associations between independent variables and drug use were examined with 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Results
The study included 6081 (75.1 %) of 8094 women who attended screening (figure 1). confounders, yet the associations remained significant. The robust relationship between IPV and drug prescription underscores the contribution of IPV to the burden on women's health.
Potentially addictive drugs may help to relieve pain, anxiety, and sleep disorders, which are all associated with IPV. [1] [2] [3] [4] The higher prescription frequency among women exposed to IPV 25 Substance use disorders and suicidal attempts are both associated with IPV, 1, 4, 12, 26 and should be assessed before such drugs are prescribed.
We cannot evaluate the appropriateness of drug prescription or the occurrence of prescription drug abuse. Yet it may be of concern that women who reported IPV more often acquired their drugs from multiple physicians. This might be an indicator of prescription drug abuse. 27 Furthermore, former studies have demonstrated that non-clinical factors such as time-saving and a feeling of inadequacy towards patients in difficult psychosocial situations influenced physicians' prescription. 28, 29 A survey among Norwegian General Practitioners also revealed that the vast majority had prescribed potentially addictive drugs even though they doubted their benefit. 30 We had no information if exposure to IPV was assessed among women in our study in connection with prescription. However, a study of rape survivors showed that the majority of those who received a prescription for sedatives and/or antidepressants, did so without disclosing the assault. 31 Moreover, women who received a prescription after they had told their physician about the rape, often felt troubled by the response. We have not found similar studies related to IPV, but it has been documented that few physicians identify IPV exposure. 32 The context of drug prescription and physicians' recognition of IPV among exposed women should be investigated in future studies. Our study was performed in an urban population of Contributors: LES contributed to the design of the study, analyzed and interpreted the data, and wrote the report. GD contributed to the study design and the interpretation of the data. AT collaborated in the statistical analysis and data management. GWJ contributed to the study 
Figure 1
Flow diagram of the study sample selection.
Respondents, additional questionnaires n=6823
Answered ≥1 violence questions n=6471
Agreed to linkage n=6238
Assessable in prescription database n=6178
Dead or emigrated before 2004 n=60
Included in study n=6081
Cancer medication n=97
Unreturned questionnaire n=1271
No information on violence n=352
Declined linkage to prescription database n=233 • Although substance abuse is common among women who have experienced IPV, former studies have not addressed the prescription of drugs with addiction potential.
• We assessed the relationship of IPV to prescription rates for potentially addictive drugs, including analgesics and central nervous system (CNS) depressants, for women in Oslo, Norway.
Key messages
• This longitudinal study showed that women who had experienced IPV, including psychological violence alone, more often received prescriptions for potentially addictive drugs compared to other women.
Strengths and limitations of this study
• A major strength is the prospective and accurate measurement of drug prescriptions from a national register. The study is population based, and adds new information about the prescription of restricted drugs with verified addictive potential to women with experiences of IPV.
• Limitations of the study include the low participation rate, and the lack of prescription data These drugs can be of clinical benefit in treatment of pain, mental distress, and insomnia; however, they do also have several adverse effects. Some of them, such as opioid analgesics and benzodiazepines, may within few weeks of use lead to physical and psychological addiction. 7, 8 The development of drug tolerance will additionally result in decreasing effectiveness and increasing dose requirements over time. Due to potential dependence and abuse the authorities have implemented control measures to restrict prescriptions for potentially addictive drugs. 9 Still, the overall prescription has increased during the past decade. 9, 10 There is limited research linking IPV and use of prescription drugs. The current knowledge is primarily based on self-reported drug use from cross-sectional studies. We did a longitudinal analysis of register-based prescription data from women in Oslo, Norway. The aim was to assess the prescription rates for potentially addictive drugs, including analgesics and CNS depressants, to women who reported physical and/or sexual IPV and psychological IPV alone.
Methods
Data sources
Our study sample was a population based cohort of women who participated in the Oslo has displayed high psychometric qualities in population-based studies. 19 Chronic musculoskeletal pain was defined as pain and/or stiffness in muscles and joints at least 3 months at a stretch last year; sleep problems as troubled by sleeplessness more than once a week. Use of potentially addictive drugs at baseline was recorded with an open question in HUBRO about drugs used the previous four weeks. Women who reported trade names of potentially addictive drugs were defined as users at baseline.
Statistical analysis
Crude and multivariable-adjusted prescription rate ratios (RR) were estimated with Poisson models with number of prescriptions as outcome. Due to overdispersion we used the negative binomial models. Nearly half of the women did not receive any potentially addictive medicine, that is a large part with zero count, and if the Vuong test favoured a zero-inflated negative binomial model we used this. The women were at risk for medicine prescriptions 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Women who reported IPV were more frequently prescribed potentially addictive drugs; i.e.
analgesics as well as CNS depressants (table 2) . The overall mean number of daily defined doses (DDD) was also higher among the group of women who had experienced IPV: 513 (95% confidence interval 359 to 667) for sexual/physical IPV; and 255 (175 to 335) for psychological IPV alone, compared to 144 (127 to 161) among other women. Furthermore, women who reported IPV were more likely to obtain prescriptions for potentially addictive drugs from multiple (≥3) physicians.
The relationship between experiences of IPV and drug prescriptions were explored further in negative binomial regression models (table 3) . Prescription rates were two times higher for women who reported psychological IPV alone, and more than three times higher for those who reported physical/sexual IPV compared to women who did not report IPV. After 
Discussion
Women with lifetime experiences of IPV received prescriptions for potentially addictive drugs two to four times more frequently than other women. The increase applied to both potentially addictive analgesics and CNS depressants, and remained significantly higher after multivariable adjustments.
A major strength of our study is the prospective and accurate measurement of drug prescriptions from a national register. 15 It substantiates previous cross-sectional findings of increased medication use among women exposed to IPV, 5, 6, 11, 14 and adds new evidence about restricted drugs with verified addictive potential. Our sample was enrolled from a large-scale survey with consent to link information to health registers. Loss to follow-up was therefore minor. While many former studies of IPV have recruited participants within health or legal services, the population-based design of the current study enabled inclusion of women regardless of help-seeking. However, the participation rate in HUBRO was low. Individuals who were unmarried, had low socioeconomic status, non-western origin, and received disability pension were underrepresented. Prevalence of IPV may therefore have been underestimated, since IPV was associated with low socioeconomic status and poor health in former studies as well as our. [1] [2] [3] [4] Actually, our prevalence estimates were lower compared with a Norwegian national survey of IPV. 2 The latter used a more comprehensive violence questionnaire with a potentially higher sensitivity than the more general questions on violence in HUBRO. Still, a study of potential non-participation bias in HUBRO found largely 26 Substance use disorders and suicidal attempts are both associated with IPV, 1, 4, 12, 27 and should be assessed before such drugs are prescribed.
We cannot evaluate the appropriateness of drug prescription or the occurrence of prescription drug abuse. Yet it may be of concern that women who reported IPV more often acquired their drugs from multiple physicians. This might be an indicator of prescription drug abuse. 28 Furthermore, former studies have demonstrated that non-clinical factors such as time-saving and a feeling of inadequacy towards patients in difficult psychosocial situations influenced physicians' prescription. 29, 30 A survey among Norwegian General Practitioners also revealed that the vast majority had prescribed potentially addictive drugs even though they doubted 31 We had no information if IPV was assessed among women in our study in connection with prescription. However, a study of rape survivors showed that the majority of those who received a prescription for sedatives and/or antidepressants, did so without disclosing the assault. 32 Moreover, women who received a prescription after they had told their physician about the rape, often felt troubled by the response. We have not found similar studies related to IPV, but it has been documented that few physicians identify IPV experiences. 33 The context of drug prescription and physicians' recognition of IPV among women who have experienced IPV should be investigated in future studies. Our study was performed in an urban population of women in Norway, a country with universal health care. External validity may be limited by differences in how health care provision is organised and financed. Access to prescription drugs may depend more on personal economic means in countries with a different kinds of insurance-based health care. It may also vary between urban and rural settings. Moreover, we did not have any data on IPV experiences among men. Similar studies should be performed in other countries and in rural settings, and include both genders.
There is still a lack of evidence on favorable health service interventions to prevent IPV and its associated adverse health outcomes. Contributors: LES contributed to the design of the study, analyzed and interpreted the data, and wrote the report. GD contributed to the study design and the interpretation of the data. AT collaborated in the statistical analysis and data management. GWJ contributed to the study design and the interpretation of the data. BS, the principal investigator, conceived the study and designed the protocol. All authors participated in drafting of the report, and approved the final version.
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